ATG16L2 and chronic myelogenous leukemia, BCR-ABL1 positive: Future studies should be aimed at analyzing a larger series of CML samples for ATG16L2 epigenetic inactivation and follow-up clinical parameters and at understanding the role it may play in CML development.